Cited by 220Acute Ischemic Stroke ManagementStatistical Methods in Clinical TrialsAcute Myocardial Infarction Research

Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale

Open access
Lansberg, Maarten G., Schrooten, Maarten, Bluhmki, Erich, Thijs, Vincent N., Saver, Jeffrey L.·2009·Stroke

Abstract

Background and Purpose— To make informed treatment decisions, patients and physicians need to be aware of the benefits and risks of a proposed treatment. The number needed to treat (NNT) for benefit and harm are intuitive and statistically valid measures to describe a treatment effect. The aim of this study is to calculate treatment time-specific NNT estimates based on shifts over the entire spectrum of clinically relevant functional outcomes. Methods— The pooled data set of the first 6 major randomized acute stroke trials of intravenous tissue plasminogen activator was used for this study. The data were stratified by 90-minute treatment time windows. NNT for benefit and NNT for harm estimates were determined based on expert generation of joint outcome distribution tables. NNT for benefit estimates were also calculated based on joint outcome distribution tables generated by a computer model. Results— NNT for benefit estimates based on the expert panel were 3.6 for patients treated between 0 and 90 minutes, 4.3 with treatment between 91 and 180 minutes, 5.9 with treatment between 181 and 270 minutes, and 19.3 with treatment between 271 and 360 minutes. The computer simulation yielded very similar results. The NNT for harm estimates for the corresponding time intervals are 65, 38, 30, and 14. Conclusions— Up to 4½ hours after symptom onset, tissue plasminogen activator therapy is associated with more benefit than harm, whereas there is no evidence of a net benefit in the 4½- to 6-hour time window. The NNT estimates for each 90-minute epoch provide useful and intuitive information based on which patients may be able to make better informed treatment decisions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/strokeaha.108.540708

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 10 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Lansberg, M. G., Schrooten, M., Bluhmki, E., Thijs, V. N., & Saver, J. L.
Affiliations
Boehringer Ingelheim (Germany) (DE)
Venue
Stroke
Published
2009-06
Volume
40
Issue
6
Pages
2079-2084
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
OpenAlex
W1968422076
Cited by
220
References
10
Citations by year
2026: 5 · 2025: 9 · 2024: 12 · 2023: 9 · 2022: 8 · 2021: 19 · 2020: 13 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 10 · 2015: 20 · 2014: 15 · 2013: 20 · 2012: 16
FWCI
9.85
Type
journal article
Language
en
Open access
Locations
  • Stroke (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Neurological Disorders and Stroke (K23NS051372)
Topics
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
tissue plasminogen activator, acute ischemic stroke, number needed to treat, therapeutic time window, intravenous thrombolysis, modified Rankin Scale, functional outcome, benefit-harm balance, computer simulation
MeSH terms
Acute Disease, Age Factors, Algorithms, Computer Simulation, Female, Fibrinolytic Agents, Humans, Male, Tissue Plasminogen Activator, Sex Factors, Time Factors, Models, Statistical, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Treatment Outcome, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review